The Motley Fool

The Surprising Sell Case For AstraZeneca plc

Today I am looking at an eye-opening reason why I believe a modest product pipeline is set to constrain earnings growth at AstraZeneca (LSE: AZN) (NYSE: AZN.US).

Pipeline problems set to persist

Shares in AstraZeneca have recovered steadily from the severe weakness of last summer, rising 9% from the same period in 2012 as optimism over the company’s pipeline-development strategy has taken off. Although the company is undoubtedly heading in the right direction, I believe that AstraZeneca is set for further heavy earnings pressure before its recovery strategy kicks revenues higher.

Sign up for FREE issues of The Motley Fool Collective. Do you want straightforward views on what’s happening with the stock market, direct to your inbox? Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio. Click here to get started now — it’s FREE!

Under new chief executive Pascal Soriot, AstraZeneca’s future revenues prospects received a huge shot in the arm through a revised growth plan announced in March. The firm is aiming to double the number of Phase III testing asset volumes by 2016, aided by the establishment of a network of R&D centres across Europe. It is also aiming to concentrate product development towards three key areas: respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology.

Although this bodes well for earnings growth over the long term, AstraZeneca still faces massive revenues upheaval in the meantime. The company’s ambitious pipeline resuscitation plans are not ready to deliver tangible returns until 2016 at the earliest, and indeed the firm’s delayed move in restructuring its R&D operations has resulted in severe earnings weakness as critical product patents have gradually expired.

AstraZeneca saw revenues slumped 18% during January-June at constant exchange rates, to $12.62bn, a result that prompted core operating profit to dip 16% to $4.38bn. Indeed, the issue of patent loss resulted in a $500m dip in revenues in the second quarter alone. And City analysts are expected the issue to continue weighing on earnings well into the future, with a 19% and 6% drop in earnings per share forecast for 2013 and 2014 respectively.

And although the company’s product testing schedule is ticking along steadily, the results of these studies — if successful — are not expected to boost earnings for some time. In positive news the firm’s Fluenz Tetra flu drug for children received a positive assessment from the European Medicines Agency last week. The company is now awaiting European Commission approval before launch, but if given the green light, launch is not expected until 2014.

AstraZeneca is also ramping up its acquisition activity in order to supplement its organic pipeline, its most recent purchase during a busy few months being cancer immunology specialists Amplimmune in late August. But as I have said, the prospect of great earnings pressure is likely to weigh heavily while the firm’s recovery measures get into gear.

The prescription for healthy shareholder returns

If further earnings pressure puts you off putting your cash into AstraZeneca, there a whole host of other FTSE 100 winners just waiting to bolster your investment returns. In this regard, I strongly recommend that you check out these recommendations from veteran fund manager Neil Woodford, which are primed with explosive growth potential.

Woodford -- in charge of UK Equities at Invesco Perpetual -- has more than 30 years' experience in the industry, and boasts an exceptional track record when it comes to selecting stock market stars.

This exclusive report, compiled by The Motley Fool's crack team of analysts, is totally free and comes with no further obligation. Click here now to download your copy.

> Royston does not own shares in AstraZeneca.